Evommune Hosts Webcast to Discuss EVO570 Licensing Deal

PUBT · 23h ago
Evommune Hosts Webcast to Discuss EVO570 Licensing Deal
  • Evommune will host a prerecorded webcast on EVO570 at 8:30 a.m. ET on Nov. 5, 2026.
  • Management will discuss the oral VAV1-directed molecular glue degrader’s licensing terms, planned rheumatoid arthritis development and role in the immunology pipeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611050630BIZWIRE_USPR_____20261105_BW854292) on November 05, 2026, and is solely responsible for the information contained therein.